Literature DB >> 17313999

PAT for vaccines: the first stage of PAT implementation for development of a well-defined whole-cell vaccine against whooping cough disease.

Mathieu Streefland1, Bas van de Waterbeemd, Hester Happé, Leo A van der Pol, E Coen Beuvery, Johannes Tramper, Dirk E Martens.   

Abstract

Since variation in process time and process output is commonly accepted to be inevitable for biological processes, application of Process Analytical Technologies (PAT) on these processes is challenging. In this paper the applicability of PAT on the cultivation of Bordetella pertussis bacteria as part of the manufacture of a vaccine against whooping cough disease is investigated. Scrutinizing and eliminating the most prominent sources of variance make the cultivation process step highly reproducible. Furthermore, the use of DNA microarrays allows investigation of how disturbances influence cellular physiology and product quality. Marker genes for product quality were identified, providing the means to quantitatively assess product quality, which is hardly possible using the mandatory animal tests for product quality. The tools and results described in this paper, combined with suitable on line measurements, can make full PAT application for this process step possible. Ultimately, the process can be designed and controlled towards consistent end product quality.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17313999     DOI: 10.1016/j.vaccine.2007.01.015

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  5 in total

1.  High-throughput FTIR-based bioprocess analysis of recombinant cyprosin production.

Authors:  Pedro N Sampaio; Kevin C Sales; Filipa O Rosa; Marta B Lopes; Cecília R C Calado
Journal:  J Ind Microbiol Biotechnol       Date:  2016-11-10       Impact factor: 3.346

2.  Small mutations in Bordetella pertussis are associated with selective sweeps.

Authors:  Marjolein van Gent; Marieke J Bart; Han G J van der Heide; Kees J Heuvelman; Frits R Mooi
Journal:  PLoS One       Date:  2012-09-28       Impact factor: 3.240

3.  Global population structure and evolution of Bordetella pertussis and their relationship with vaccination.

Authors:  Marieke J Bart; Simon R Harris; Abdolreza Advani; Yoshichika Arakawa; Daniela Bottero; Valérie Bouchez; Pamela K Cassiday; Chuen-Sheue Chiang; Tine Dalby; Norman K Fry; María Emilia Gaillard; Marjolein van Gent; Nicole Guiso; Hans O Hallander; Eric T Harvill; Qiushui He; Han G J van der Heide; Kees Heuvelman; Daniela F Hozbor; Kazunari Kamachi; Gennady I Karataev; Ruiting Lan; Anna Lutyńska; Ram P Maharjan; Jussi Mertsola; Tatsuo Miyamura; Sophie Octavia; Andrew Preston; Michael A Quail; Vitali Sintchenko; Paola Stefanelli; M Lucia Tondella; Raymond S W Tsang; Yinghua Xu; Shu-Man Yao; Shumin Zhang; Julian Parkhill; Frits R Mooi
Journal:  mBio       Date:  2014-04-22       Impact factor: 7.867

4.  Genome-wide gene expression analysis of Bordetella pertussis isolates associated with a resurgence in pertussis: elucidation of factors involved in the increased fitness of epidemic strains.

Authors:  Audrey J King; Saskia van der Lee; Archena Mohangoo; Marjolein van Gent; Arno van der Ark; Bas van de Waterbeemd
Journal:  PLoS One       Date:  2013-06-11       Impact factor: 3.240

5.  Naturally circulating pertactin-deficient Bordetella pertussis strains induce distinct gene expression and inflammatory signatures in human dendritic cells.

Authors:  Michiel M Kroes; Alberto Miranda-Bedate; Elise S Hovingh; Ronald Jacobi; Corrie Schot; Elder Pupo; René H M Raeven; Arno A J van der Ark; Jos P M van Putten; Jelle de Wit; Rob Mariman; Elena Pinelli
Journal:  Emerg Microbes Infect       Date:  2021-12       Impact factor: 7.163

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.